Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology
- PMID: 34482706
- PMCID: PMC8649542
- DOI: 10.1161/JAHA.121.021686
Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology
Erratum in
-
Correction to: Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology.J Am Heart Assoc. 2023 May 16;12(10):e027687. doi: 10.1161/JAHA.121.027687. Epub 2023 May 9. J Am Heart Assoc. 2023. PMID: 37158160 Free PMC article. No abstract available.
Abstract
Radiation therapy demonstrates a clear survival benefit in the treatment of several malignancies. However, cancer survivors can develop a wide array of cardiotoxic complications related to radiation. This pathology is often underrecognized by clinicians and there is little known on how to manage this population. Radiation causes fibrosis of all components of the heart and significantly increases the risk of coronary artery disease, cardiomyopathy, valvulopathy, arrhythmias, and pericardial disease. Physicians should treat other cardiovascular risk factors aggressively in this population and guidelines suggest obtaining regular imaging once symptomatology is established. Patients with radiation-induced cardiovascular disease tend to do worse than their traditional counterparts for the same interventions. However, there is a trend toward fewer complications and lower mortality with catheter-based rather than surgical approaches, likely because radiation makes these patients poor surgical candidates. When appropriate, these patients should be referred for percutaneous management of valvulopathy and coronary disease.
Keywords: cancer survivors; cardiomyopathies; cardiotoxicity; cardiovascular diseases; coronary artery disease; fibrosis; heart disease risk factors.
Conflict of interest statement
None.
Figures
Similar articles
-
Radiation-Induced Cardiovascular Disease.Curr Atheroscler Rep. 2017 May;19(5):22. doi: 10.1007/s11883-017-0658-x. Curr Atheroscler Rep. 2017. PMID: 28315200 Review.
-
Contemporary Understandings of Cardiovascular Disease After Cancer Radiotherapy: a Focus on Ischemic Heart Disease.Curr Cardiol Rep. 2020 Sep 23;22(11):151. doi: 10.1007/s11886-020-01380-4. Curr Cardiol Rep. 2020. PMID: 32964267 Review.
-
Radiation Toxicity to the Cardiovascular System.Curr Oncol Rep. 2016 Mar;18(3):15. doi: 10.1007/s11912-016-0502-4. Curr Oncol Rep. 2016. PMID: 26838585 Review.
-
Cardiovascular complications after radiotherapy.Cardiol J. 2020;27(6):836-847. doi: 10.5603/CJ.a2018.0120. Epub 2018 Oct 19. Cardiol J. 2020. PMID: 30338841 Free PMC article. Review.
-
Cardiac complications of oncologic therapy.Radiographics. 2013 Oct;33(6):1801-15. doi: 10.1148/rg.336125005. Radiographics. 2013. PMID: 24108563 Review.
Cited by
-
Heart is a heavy burden: cardiac toxicity in radiation oncology.Support Care Cancer. 2024 Nov 4;32(11):769. doi: 10.1007/s00520-024-08949-7. Support Care Cancer. 2024. PMID: 39495349 Review.
-
Cardiovascular disease in thymic cancer patients.Front Cardiovasc Med. 2024 Sep 10;11:1393631. doi: 10.3389/fcvm.2024.1393631. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39346095 Free PMC article.
-
Cardiovascular adaptations and pathological changes induced by spaceflight: from cellular mechanisms to organ-level impacts.Mil Med Res. 2024 Sep 27;11(1):68. doi: 10.1186/s40779-024-00570-3. Mil Med Res. 2024. PMID: 39334239 Free PMC article. Review.
-
The potential treatment of N-acetylcysteine as an antioxidant in the radiation-induced heart disease.Cardiovasc Diagn Ther. 2024 Aug 31;14(4):509-524. doi: 10.21037/cdt-24-19. Epub 2024 Aug 21. Cardiovasc Diagn Ther. 2024. PMID: 39263473 Free PMC article.
-
Radiation-associated cardiovascular disease in patients with cancer: current insights from a cardio-oncologist.J Radiat Res. 2024 Sep 24;65(5):575-590. doi: 10.1093/jrr/rrae068. J Radiat Res. 2024. PMID: 39256035 Free PMC article. Review.
References
-
- Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, et al. Cardiac toxicity after radiotherapy for stage III non‐small‐cell lung cancer: pooled analysis of dose‐escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35:1387–1394. doi: 10.1200/JCO.2016.70.0229 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical